Published in World J Gastroenterol on October 21, 2014
Lack of Association Found between Helicobacter pylori Infection and Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Retrospective Study. Gastroenterol Res Pract (2016) 1.08
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore) (2016) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology (2013) 8.37
Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol (2004) 7.23
Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology (1998) 5.34
The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology (2007) 5.04
A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med (1995) 5.02
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2003) 3.84
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut (2008) 3.81
A patient questionnaire to identify bowel disease. Ann Intern Med (1989) 3.43
The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med (2006) 3.30
Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut (1983) 2.93
Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol (2004) 2.71
Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol (2008) 2.52
Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2011) 2.42
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut (2006) 2.33
Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol (1998) 2.24
Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol (2000) 2.20
Postinfectious irritable bowel syndrome. Gastroenterology (2003) 2.12
Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut (2007) 2.11
Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther (2001) 2.04
Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil (2007) 1.98
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther (2011) 1.97
Volume, composition, and source of intestinal gas. Gastroenterology (1970) 1.97
Abnormal colonic fermentation in irritable bowel syndrome. Lancet (1998) 1.91
Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol (2011) 1.88
Attention and distraction: effects on gut perception. Gastroenterology (1997) 1.87
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
The role of intestinal gas in functional abdominal pain. N Engl J Med (1975) 1.85
Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology (2002) 1.80
Review article: abdominal bloating and distension in functional gastrointestinal disorders--epidemiology and exploration of possible mechanisms. Aliment Pharmacol Ther (2007) 1.71
Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology (2006) 1.69
A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol (2006) 1.67
Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology (2004) 1.66
Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology (2009) 1.62
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil (2005) 1.60
5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil (2008) 1.59
Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol (2003) 1.59
Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy (2004) 1.57
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2001) 1.52
Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci (2000) 1.50
Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol (1999) 1.49
Intestinal tone and gas motion. Neurogastroenterol Motil (2006) 1.44
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol (2005) 1.44
Associations between symptoms of irritable colon and psychological and social conditions and lifestyle. Br Med J (Clin Res Ed) (1986) 1.44
Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol (2001) 1.40
Functional bowel disease: malabsorption and abdominal distress after ingestion of fructose, sorbitol, and fructose-sorbitol mixtures. Gastroenterology (1988) 1.38
Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology (1991) 1.34
An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol (2003) 1.34
Methanogens outcompete sulphate reducing bacteria for H2 in the human colon. Gut (1994) 1.32
The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther (2005) 1.32
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut (1999) 1.31
Impaired gastric accommodation and its role in dyspepsia. Gut (2006) 1.31
Factors affecting hydrogen production and consumption by human fecal flora. The critical roles of hydrogen tension and methanogenesis. J Clin Invest (1992) 1.30
Physiological basis of gas exchange in the gut. Ann N Y Acad Sci (1968) 1.29
Intestinal gas dynamics and tolerance in humans. Gastroenterology (1998) 1.28
Gender differences in irritable bowel symptoms. Eur J Gastroenterol Hepatol (1997) 1.23
Prolonged balloon expulsion is predictive of abdominal distension in bloating. Am J Gastroenterol (2010) 1.22
Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. Aliment Pharmacol Ther (2013) 1.21
Dyspepsia: organic versus functional. J Clin Gastroenterol (2012) 1.20
Colonic responses to gas loads in subgroups of patients with abdominal bloating. Am J Gastroenterol (2010) 1.18
Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. Gut (1983) 1.17
Antro-fundic dysfunctions in functional dyspepsia. Gastroenterology (2003) 1.16
Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol (2012) 1.14
Prokinetic effects in patients with intestinal gas retention. Gastroenterology (2002) 1.14
Origin of gas retention and symptoms in patients with bloating. Gastroenterology (2005) 1.13
Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol (2006) 1.13
Gastrointestinal symptoms and obesity: a meta-analysis. Obes Rev (2011) 1.12
Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol (2001) 1.12
Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut (1991) 1.12
Symptoms and physiology in severe chronic constipation. Am J Gastroenterol (1999) 1.11
Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil (2004) 1.11
A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr (2002) 1.09
Gender role and irritable bowel syndrome: literature review and hypothesis. Am J Gastroenterol (2000) 1.09
Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut (2008) 1.09
The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.09
Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol (2008) 1.07
Sugar malabsorption in functional bowel disease: clinical implications. Am J Gastroenterol (1993) 1.06
Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology (2001) 1.05
Exclusion diets in irritable bowel syndrome: are they worthwhile? J Clin Gastroenterol (1987) 1.05
The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther (2002) 1.04
A formal approach to symptoms in dyspepsia. Clin Gastroenterol (1985) 1.03
Modulation of gut perception in humans by spatial summation phenomena. J Physiol (1998) 1.03
Prevalence of functional dyspepsia and its subgroups in patients with eating disorders. World J Gastroenterol (2012) 1.02
Impaired viscerosomatic reflexes and abdominal-wall dystony associated with bloating. Gastroenterology (2006) 1.02
Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol (2009) 1.02
Intestinal gas distribution determines abdominal symptoms. Gut (2003) 1.02
Abdominal bloating. Gastroenterology (2005) 1.01
Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol (2014) 1.00
Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol (2014) 0.99
Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology (2006) 0.99
Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol. Scand J Gastroenterol (1992) 0.99
Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol (1989) 0.99
Gastric distension and duodenal lipid infusion modulate intestinal gas transit and tolerance in humans. Am J Gastroenterol (2002) 0.99
A prospective study of unexplained visible abdominal bloating. N Z Med J (1994) 0.97
Reflex control of intestinal gas dynamics and tolerance in humans. Am J Physiol Gastrointest Liver Physiol (2003) 0.97